A blood-based liquid biopsy test detects early-onset colorectal cancer with strong diagnostic performance and high ...

Forbes contributors publish independent expert analyses and insights. I cover cancer science, treatments and attitudes. The investigators purified and marked high levels of exosomes from blood of ...

ExosomeDx harnesses biological information from exosomes for biomarker discovery and diagnostic development. The company’s pipeline of products includes the ExoDx Prostate test, the first ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc. presented data that sets a new standard for EGFR-T790M resistance mutation detection in lung cancer, with the highest sensitivity reported ...

A few years ago, a team of MIT scientists developed a novel way to separate blood cells using sound waves. Now the team, in conjunction with scientists from several other institutions, has taken the ...

Earlier this year, Exosome Diagnostics said that it would scout out deals with biopharma partners to gain ground with its liquid biopsy tests. Now, the company is ...

Exosome Diagnostics is trotting out promising data for its lung cancer liquid biopsy test, a week after reeling in new funds to support development of its liquid biopsy technology and build out its ...

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced data demonstrating the ability of its plasma ...

MINNEAPOLIS, March 18, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract ...

Exosome Diagnostics, Inc., announced today that it has executed an agreement to provide its prostate cancer risk assessment test, ExoDx® Prostate(IntelliScore), or EPI, through FedMed, Inc., a ...